Biomarkers for Hepatocellular Carcinoma Based on Body Fluids and Feces

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2021 May 27

PMID 34040698

Citations 7

Authors

Ming-Cheng Guan

Wei Ouyang

Ming-Da Wang

Lei Liang

Na Li

Ting-Ting Fu

Feng Shen

Wan-Yee Lau

Qiu-Ran Xu

Dong-Sheng Huang

Hong Zhu

Tian Yang

Affiliations

Soon will be listed here.

Abstract

Novel non-/minimally-invasive and effective approaches are urgently needed to supplement and improve current strategies for diagnosis and management of hepatocellular carcinoma (HCC). Overwhelming evidence from published studies on HCC has documented that multiple molecular biomarkers detected in body fluids and feces can be utilized in early-diagnosis, predicting responses to specific therapies, evaluating prognosis before or after therapy, as well as serving as novel therapeutic targets. Detection and analysis of proteins, metabolites, circulating nucleic acids, circulating tumor cells, and extracellular vesicles in body fluids (, blood and urine) and gut microbiota (, in feces) have excellent capabilities to improve different aspects of management of HCC. Numerous studies have been devoted in identifying more promising candidate biomarkers and therapeutic targets for diagnosis, treatment, and monitoring responses of HCC to conventional therapies, most of which may improve diagnosis and management of HCC in the future. This review aimed to summarize recent advances in utilizing these biomarkers in HCC and discuss their clinical significance.

Citing Articles

Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma.

Guan M, Wang M, Wang W, Li C, Yao L, Zhu H Liver Res. 2025; 6(3):132-138.

PMID: 39958202 PMC: 11791807. DOI: 10.1016/j.livres.2022.08.001.

Assessing the Predictive Accuracy of the aMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis.

Elgenidy A, Abubasheer T, Odat R, Abdelrahim M, Jibril N, Ramadan A J Clin Exp Hepatol. 2024; 15(1):102381.

PMID: 39262566 PMC: 11386263. DOI: 10.1016/j.jceh.2024.102381.

Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.

Yao L, Fan Z, Wang M, Diao Y, Chen T, Zeng Y Ann Surg Oncol. 2023; 31(2):1219-1231.

PMID: 37925654 DOI: 10.1245/s10434-023-14525-w.

Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.

Panneerselvam S, Wilson C, Kumar P, Abirami D, Pamarthi J, Reddy M Cell Adh Migr. 2023; 17(1):1-21.

PMID: 37726886 PMC: 10512929. DOI: 10.1080/19336918.2023.2258539.

The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis.

Guan M, Zhang S, Ding Q, Li N, Fu T, Zhang G J Clin Med. 2023; 12(3).

PMID: 36769597 PMC: 9918029. DOI: 10.3390/jcm12030949.

References

Ponziani F, Nicoletti A, Gasbarrini A, Pompili M . Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919848184. PMC: 6535703. DOI: 10.1177/1758835919848184. View

Abdalla M, Haj-Ahmad Y . Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012; 3:390-403. PMC: 3471080. DOI: 10.7150/jca.4280. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

Mann J, Reeves H, Feldstein A . Liquid biopsy for liver diseases. Gut. 2018; 67(12):2204-2212. DOI: 10.1136/gutjnl-2017-315846. View

Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H . Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res. 2012; 11(8):4361-72. DOI: 10.1021/pr300502v. View

G Ladep N, Dona A, Lewis M, Crossey M, Lemoine M, Okeke E . Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology. 2014; 60(4):1291-301. DOI: 10.1002/hep.27264. View

Guo W, Sun Y, Shen M, Ma X, Wu J, Zhang C . Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. Clin Cancer Res. 2018; 24(9):2203-2213. DOI: 10.1158/1078-0432.CCR-17-1753. View

Shen T, Li S, Wang J, Zhang T, Zhang S, Chen H . TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy. Liver Int. 2020; 40(11):2834-2847. DOI: 10.1111/liv.14581. View

Al-Ameri A, Wei X, Lin L, Shao Z, Guo H, Xie H . Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019; 19(1):1136. PMC: 6873730. DOI: 10.1186/s12885-019-6343-4. View

10.

Chen R, Xu X, Tao Y, Qian Z, Yu Y . Exosomes in hepatocellular carcinoma: a new horizon. Cell Commun Signal. 2019; 17(1):1. PMC: 6323788. DOI: 10.1186/s12964-018-0315-1. View

11.

Yang J, Addissie B, Mara K, Harmsen W, Dai J, Zhang N . GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2018; 28(3):531-538. PMC: 6401221. DOI: 10.1158/1055-9965.EPI-18-0281. View

12.

Ng S, Jang G, Kurland I, Qiu Y, Guha C, Dawson L . Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy. EBioMedicine. 2020; 59:102973. PMC: 7484529. DOI: 10.1016/j.ebiom.2020.102973. View

13.

Rattan P, Minacapelli C, Rustgi V . The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020; 26(10):1316-1327. DOI: 10.1002/lt.25828. View

14.

Wang Q, Su B, Dong L, Jiang T, Tan Y, Lu X . Liquid Chromatography-Mass Spectrometry-Based Nontargeted Metabolomics Predicts Prognosis of Hepatocellular Carcinoma after Curative Resection. J Proteome Res. 2020; 19(8):3533-3541. DOI: 10.1021/acs.jproteome.0c00344. View

15.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

16.

Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G . A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2017; 67(2):662-675. PMC: 6680350. DOI: 10.1002/hep.29561. View

17.

Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J . Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020; 12(1):102. PMC: 7682083. DOI: 10.1186/s13073-020-00796-5. View

18.

Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O . Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. mSystems. 2020; 5(3). PMC: 7300357. DOI: 10.1128/mSystems.00153-20. View

19.

Abdalla M, Haj-Ahmad Y . Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012; 3:19-31. PMC: 3245605. DOI: 10.7150/jca.3.19. View

20.

Singal A, Lampertico P, Nahon P . Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72(2):250-261. PMC: 6986771. DOI: 10.1016/j.jhep.2019.08.025. View